phase i/ii studi cyclophosphamid doxorubicin fluorouracil leucovorin treatment metastat adenocarcinoma leucovorin cytotox fluorouracil patient colorect cancer efficaci combin chemotherapi maximum dose leucovorin use combin cyclophosphamid doxorubicin phase i/ii trial patient dose leucovorin day cyclophosphamid day doxorubicin day constant dose cohort patient day cycl week signific mucos diarrhea myelosuppress patient day contrast dose day patient granulocyt count nadir first cycl therapi platelet count addit patient dose signific mucos toxic effect insuffici recoveri second cours day patient assess breast cancer complet partial respons respons rate leucovorin modul combin chemotherapi cyclophosphamid doxorubicin activ regimen treatment metastat breast cancer further studi addit leucovorin activ regimen 